EUVIMEDEUVIMED entdecken
Klinische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria

Regis Peffault de Latour, Austin Kulasekararaj iD, David Dingli, Koo Wilson, Piotr Wojciechowski, Zalmai Hakimi, Jameel Nazir, Barbara Czech, Peter Hillmen, Jeff Szer

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14422 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Regis Peffault de Latour und 9 weiteren Autor:innen. Beteiligte Einrichtung: French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Complement Inactivating Agents, Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Orphan Biovitrum, Swedish Orphan Biovitrum AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired non‐malignant haematological disorder characterised by thrombosis risk, serious complications and debilitating symptoms in untreated patients.

Objective

This anchored indirect treatment comparison (ITC) evaluated efficacy data between proximal complement 3 inhibitor (C3i) pegcetacoplan and factor B inhibitor, iptacopan, in patients with PNH previously treated with complement 5 inhibitors (C5i; eculizumab, ravulizumab).

Methods

Respective pivotal studies provided patient‐level trial data for pegcetacoplan (16‐week PEGASUS [NCT03500549]) and published data for iptacopan (24‐week APPLY PNH [NCT04558918]). Differences in study design, duration and statistical methods between PEGASUS and APPLY PNH necessitated the comparative analyses to be conducted on secondary measures based on haemoglobin (Hb) levels, absolute reticulocyte count (ARC), lactate dehydrogenase (LDH) levels, and patient‐reported outcomes on the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐Fatigue) scale scores. The availability of a common reference C5i treatment group in both PEGASUS and APPLY PNH studies allowed anchored ITC (Bucher method). Simulated treatment comparison (STC) assessed the robustness of the main analysis.

Results

Overall, baseline characteristics of the populations in the PEGASUS and APPLY PNH studies were broadly comparable. Anchored ITC showed comparable outcomes (mean difference, [95% CI]) on change‐from‐baseline to end of study for pegcetacoplan versus C5i, and iptacopan versus C5i, respectively, across endpoints: Hb level ( − 0.49 g/dL [ − 1.78, 0.80]); ARC ( – 34.41 × 10 9 /L [ − 90.02, 21.21]); LDH level ( − 115.16 U/L [ − 244.40, 14.01]); FACIT‐Fatigue score (3.57 [ − 5.60, 12.73]). Finally, the STC produced results consistent with the main Bucher analyses across all clinical endpoints and patient‐reported fatigue, providing similar point estimates and confidence intervals.

Conclusion

This anchored ITC, based on data from pivotal trials, did not indicate significant differences in clinical or patient‐reported outcomes between pegcetacoplan and iptacopan in PNH treatment. The findings suggest that PNH treatment decisions should also consider individualised disease‐ and patient‐related factors. Trial Registration: ClinicalTrials.gov identifier: NCT03500549.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedComplement Inactivating AgentsHemoglobinuria, ParoxysmalAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeBenzoatesIndolesPiperidines

Stichwörter der Autor:innen

indirect treatment comparisoniptacopanparoxysmal nocturnal haemoglobinuriapegcetacoplan

Substanzen

Antibodies, Monoclonal, HumanizedComplement Inactivating AgentseculizumabiptacopanravulizumabBenzoatesIndolesPiperidines

Autor:innen und Institutionen

  • French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France.
  • Department of Haematological Medicine, King's College Hospital, National Institute of Health Research/Wellcome King's Clinical Research Facility, London, UK.
  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, USA.
  • Swedish Orphan Biovitrum AB (Sobi), Stokholm, Sweden.
  • Clever-Access, Krakow, Poland.
  • Apellis Pharmaceuticals, Boston, Massachusetts, USA.

ORCID-Profile: Austin Kulasekararaj

Förderung

  • Swedish Orphan Biovitrum
  • Swedish Orphan Biovitrum AB

Zitieren

APA

de Latour, R. P., Kulasekararaj, A., Dingli, D., Wilson, K., Wojciechowski, P., Hakimi, Z., Nazir, J., Czech, B., Hillmen, P., & Szer, J. (2025). Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria. European Journal of Haematology. https://doi.org/10.1111/ejh.14422

Vancouver

de Latour RP, Kulasekararaj A, Dingli D, Wilson K, Wojciechowski P, Hakimi Z, et al. Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria. European Journal of Haematology. 2025. doi:10.1111/ejh.14422

BibTeX
@article{deLatour2025,
  author = {de Latour, Regis Peffault and Kulasekararaj, Austin and Dingli, David and Wilson, Koo and Wojciechowski, Piotr and Hakimi, Zalmai and Nazir, Jameel and Czech, Barbara and Hillmen, Peter and Szer, Jeff},
  title = {Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14422}
}
Kostenlos starten →